language_icon
EN
HI

Biocon Share price

BIOCON

369.45

11.50 (-3.02%)
NSE
BSE
Last updated on 23 Mar, 2026 | 12:17 IST
Today's High

378.40

Today's Low

369.20

52 Week Low

299.00

52 Week High

424.95

Zero AMC

Free Demat with Zero AMC*

Open a Free Demat Account
+ Free 1st Year AMC

Biocon Chart

Biocon Share Key Metrics

Volume
7.22 L
Market Cap
61748.48 CR
LTQ@LTP
140@369.45
ATP
372.42
Var Margin
15.3 %
Circuit Range
342.9-419
Delivery %
67.71 %
Value
26.89 CR
ASM/GSM
No
Market Lot
1

Summary

At 23 Mar, 2026 | 12:17, Biocon share price stands at ₹369.45, showing a 11.50% -3.02 for the day. The stock’s intraday movement has stayed between ₹369.20 and ₹378.40, while on a 52-week basis it has fluctuated from ₹299.00 to ₹424.95.
In terms of trading activity, Biocon has recorded a volume of 721934 shares, with a market capitalisation of ₹1620907773. The stock’s Average Traded Price (ATP) stands at ₹37242, while the Last Traded Quantity at Last Traded Price (LTQ@LTP) is 140,36945. The stock operates within a circuit range of ₹342.9-419, with a Value of ₹26.89 CR. The Delivery Percentage for the day is 67.71%. Additionally, Biocon currently falls under the No framework, and trades with a market lot size of 1.

Biocon Fundamentals

View More
P/E Ratio

102.19

P/B Ratio

1.63

Div. Yield

0.13

Sector P/E

60

Sector P/B

2.64

Sec. Div. Yield

0.59

Biocon Resistance and Support

Pivot 377.85

Resistance

First Resistance

385.75

Second Resistance

390.55

Third Resistance

398.45

Support

First Support

373.05

Second Support

365.15

Third Support

360.35

Biocon Futures & Options

369.45

-11.5 (-3.02%)

link_white_icon

Biocon Option Chain

View Price, OI, Greeks & More...
View All

30MAR26

369.40

-11.15 (2.93%)

28APR26

371.85

-11.00 (2.87%)

26MAY26

374.00

-10.55 (2.74%)

BIOCON|30MAR26 CE 365.00

11.10

-6.7 (-37.64%)

BIOCON|30MAR26 PE 370.00

8.65

4.7 (118.99%)

Biocon Shareholding Pattern

View More
  • 2016-17
  • 2018-19
  • 2019-20
  • 2020-21
  • 2021-22
  • 2022-23
  • 2023-24
  • 2024-25
  • 2025-26
Total Promoters
Segment
Percent

Total Promoters

54.45%

Mutual Fund

13.75%

Insurance

6.9%

Foreign Institutional Investors

7.39%

Domestic Institutional Investors

1.06%

Retail

16.45%

Others

0%

Total Promoters
MAR '25
60.64%
JUN '25
54.45%
SEP '25
54.45%
DEC '25
54.45%

Biocon Corporate Actions

DateAgenda
2026-02-12Quarterly Results
2025-11-11Quarterly Results
2025-10-01Redemption (Part) of NCD
2025-08-07Quarterly Results
2025-05-08Audited Results & Final Dividend
2025-04-23Others
2025-04-04To consider Fund Raising
2025-01-30Quarterly Results & Others
2025-01-27Others

Biocon News

Biocon Limited

Biocon Pharma, a wholly-owned subsidiary, received US FDA approval for its Liraglutide Injection (gVictoza®) for Type 2 Diabetes. This approval strengthens Biocon's portfolio of vertically integrated, complex drug products.
Mar 12 2026 21:03:00

Biocon Ltd - 532523 - Notification To Stock Exchanges

Biocon Pharma, a wholly-owned subsidiary of Biocon, secured US FDA approval for its Liraglutide Injection ANDA (gVictoza®). This approval for Type 2 Diabetes Mellitus treatment strengthens Biocon's vertically integrated, complex drug product portfolio.
Mar 12 2026 21:03:00
Read More

About Biocon

NSE : 11373  
BSE : 532523  
ISIN : INE376G01013  

HISTORY AND CERTAIN CORPORATE MATTERSOur Company was incorporated as Biocon India Private Limited onNovember 29 1978 under the Companies Act. The word `Private' wasdeleted from our name under the provisions of Section 43A(2) of theCompanies Act with effect from July 1 1995. Thereafter our Company wasconverted to a private limited company under the provisions of Section43(2A) of the Companies Act with effect from December 21 2000. It wasreconverted into a public limited company on June 18 2001. The name ofour Company was changed from Biocon India Limited to Biocon Limited anda fresh certificate of incorporation consequent on change of name wasissued by the RoC on November 19 2003.Our Corporate StructureOur existing corporate structure is as under:Biocon LimitedClinigene International PrivateLimited (100.00%)Biocon Biopharmaceuticals PrivateLimited (51.00%)Syngene International PrivateLimited (99.99%)Interest of Promoters Directors and Key Managerial PersonnelExcept as stated in ?Related Party Transactions? on page 84 of this RedHerring Prospectus and to the extent of shareholding in our Companythe Promoters do not have any other interest in our business.Our Promoters have significant rights in our Company under the terms ofour Articles of Association. For additional information please referto the section entitled ?Main Provisions of Articles of Association ofBiocon Limited? on page 168 of this Red Herring Prospectus.Except to the extent of their compensation and to the extent of ESOPif any as mentioned on page 165 of this Red Herring Prospectus andtheir shareholding or shareholding of companies they represent theDirectors other than Promoter Directors do not have any otherinterest in our Company. Our Director Mr. John Shaw is the husband ofour Chairman & Managing Director Ms. Kiran Mazumdar-Shaw. OurDirector Prof. Ravi Mazumdar is the brother of our Chairman & ManagingDirector Ms. Kiran Mazumdar-Shaw. Our alternate Director Prof.Catherine Rosenberg is the sister-in-law of our Chairman & ManagingDirector Ms. Kiran Mazumdar-Shaw.The key managerial personnel of our Company do not have any interest inour Company other than to the extent of the remuneration or benefits towhich they are entitled to as per their terms of appointment andreimbursement of expenses incurred by them during the ordinary courseof business and to the extent of the Equity Shares held by them in theCompany if any and options granted to them under the ESOP.

Read More

Biocon Management

NamePosition
Ms. Kiran Mazumdar Shaw Executive Chairperson
Mr. Siddharth Mittal Managing Director & CEO
View More

Biocon FAQs

The Buying Price of Biocon share is 369.45 For live prices and instant trading, you can log in to your Choice trading account or open a Free Demat account with Choice.

To buy Biocon stocks, log in to your Choice trading account. If you don’t have one, open a Choice Demat account. Then, add funds, search for Biocon, choose your preferred order type, and place the trade.

The Price-to-earnings (P/E) ratio of Biocon shares is 102.19. You can compare it with the sector average for relative valuation.

The Price to Book (P/B) ratio Biocon shares is 1.63. Useful to assess the stock's value relative to its book value.

To assess Biocon’s valuation compare Sector P/E, P/B which are 60 & 2.64 with sector averages, along with growth rates and financial metrics.

The Market Cap of Biocon is 61748.48 CR. It indicates the company's size category and trading liquidity.

The 52 week high and low prices of Biocon share price is 424.95 & 299.00. They indicate price extremes, trading ranges, volatility measures, potential support/resistance, and price momentum.

Biocon belongs to the Healthcare sector.

Invest with Zero-Cost Demat Account

Zero AMC for First Year
Free Research Calls
₹ 0 Trade & Call Fee
Zero-Cost